Han-Sung Kang

Han-Sung Kang

Auto-generated profile, based on publicly available information

Han-Sung Kang

Center for Breast Cancer National Cancer Center Goyang Republic of Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
HKHyunhee Kim
Hyunhee Kim
JHJaihong Han
Jaihong Han
Sun-Young KimSun-Young Kim
Sun-Young Kim
ELEun Sook Lee
Eun Sook Lee
HKHan-Sung Kang
Han-Sung Kang
ELEun-Gyeong Lee
Eun-Gyeong Lee
Kim H, et al. J Breast Cancer. 2021 Dec;24:e48. https://doi.org/10.4048/jbc.2021.24.e48

1 June 2020 in Korean Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
HJHeein Jo
Heein Jo
ELEun-Gyeong Lee
Eun-Gyeong Lee
ESEunjin Song
Eunjin Song
JHJaihong Han
Jaihong Han
SJSo-Youn Jung
So-Youn Jung
SLSeeyoun Lee
Seeyoun Lee
The ACOSOG Z0011 trial has proven the oncological safety of sentinel lymph node biopsy (SLBx) for node negative breast cancer. Accordingly, treatment paradigm including axilla surgery was changed. We retrospectively reviewed breast cancer patients to evaluate the clinical effect of paradigm shift in breast cancer surgery after applying the Z0011 criteria. All women who underwent breast-conserving surgery at the National Cancer Center between January 1, 2000, and December 31, 2015, were enrolled and classified according to the Z0011 criteria. The primary endpoint of the study was the disease-free survival rates, and the secondary was the adverse events, especially arm lymphedema. Total 361 patients were enrolled the study (271 axillary lymph node dissection [ALND] group, 90 SLBx group). After the Z0011 guideline was adopted in our institute, the use of ALND decreased, and lymph node sampling (removing only a few axillary lymph nodes) replaced ALND. The total mean number of retrieved nodes were more in ALND group (13.02) than SLBx group (3.43). However, there was no difference in the mean number of positive nodes between two groups (2.34 in ALND group vs. 1.12 in SLBx group, P=0.001). During follow-up, 25 patients experienced disease recurrence: 22 from the ALND group and three from the SLBx group. All of died seven patients were from the ALND group. The ALND group had more complications than the SLBx group (P=0.02). Arm edema occurred more frequently in the ALND group (29.5%) than in the SLBx group (5.6%), although without statistical significance (P=0.07). In our study, we concluded that SLBx can be used safely in Z0011-eligible cohort without increased risk of locoregional recurrence. Moreover, we found that omission of ALND is favored to reduce some serious complications such as arm lymphedema.

24 February 2025 in ESMO Open
Verified
Journal Article
Open access
MKMin-Chae Kang
Min-Chae Kang
SLSeeyoun Lee
Seeyoun Lee
HKH. Kim
H. Kim
HKH.-S. Kang
H.-S. Kang
SJSo-Youn Jung
So-Youn Jung
SKSun-Young Kong
Sun-Young Kong
Germline PALB2 variants increase the risks of various cancers. However, these have not been comprehensively investigated in Korean patients with cancer. Our study aimed to evaluate the prevalence and clinical characteristics of PALB2 germline variants in Korean patients with cancer and compare these findings with existing data. We analyzed the clinicopathological and germline next-generation sequencing data of 3987 patients with cancer from the National Cancer Center in Korea. Additionally, we carried out functional analysis of the PALB2 splicing variant, c.3350+5G>A. A total of 104 patients presented PALB2 germline variants with eight pathogenic variants (PVs), 14 likely pathogenic variants (LPVs), and 82 variants of uncertain significance (VUS). PALB2 PV/LPVs were detected at an overall frequency of 0.6% (22/3987) across all patients. Among patients with PV/LPVs, 95.5% were women, and 19 and 3 carriers were diagnosed with breast and ovarian cancer, respectively. Further, we reclassified c.3350+5G>A as a PV rather than VUS, according to the American College of Medical Genetics and Genomics guidelines. Patients with PALB2 PV/LPVs had a younger age at first cancer diagnosis (44.6 ± 10.1 years versus 50.2 ± 12.0 years, P = 0.019) and were more likely to have multiple primary organ cancer diagnoses (22.7% versus 8.3%, P = 0.032) compared with those without these variants. Age at first cancer diagnosis and the presence of multiple primary organ cancers are key risk factors for suspected germline PALB2 PV. Hence, strategies are required to improve adherence to the National Comprehensive Cancer Network guidelines for cancer screening and family genetic testing among Korean patients with cancer.

6 February 2022
Verified
Conference Paper
Closed access
HKHansung Kang
Hansung Kang
YLYong-Joo Lee
Yong-Joo Lee
DCDongbin Cho
Dongbin Cho
JLJaeyoung Lee
Jaeyoung Lee
MKMincheal Kang
Mincheal Kang
JSJiwon Seo
Jiwon Seo
As the DNN model becomes more complex, the number of parameters constituting the model increases and requires a large amount of computation. Recently, a quantization technique that reduces the memory of the model and enables efficient computation has been studied. In this paper, we propose Fake Single Precision Training (FST) to increase accuracy by using a high bit range for weight and a low bit range for activation output with a certain probability. FST improved the accuracy of the model by applying the features of Google's Quantization Aware Training and FaceBook's Quant Noise method.

16 October 2026 in Cancer Science
Verified
Journal Article
Open access
PDF file
MKMin-Chae Kang
Min-Chae Kang
HLHa‐Eun Lee
Ha‐Eun Lee
SPSang-Yoon Park
Sang-Yoon Park
SLSeeyoun Lee
Seeyoun Lee
SJSo-Youn Jung
So-Youn Jung
SKSun-Young Kong
Sun-Young Kong
Germline pathogenic/likely pathogenic (P/LP) variants inform cancer treatment and prevention, yet real‐world detection patterns and downstream clinical management remain poorly characterized in East Asian hereditary cancer cohorts. This retrospective cohort study included 5829 patients with cancer who underwent germline testing at the National Cancer Center, Republic of Korea, between April 2006 and April 2023 using BRCA1/2 ‐only testing or multigene panel testing. We examined P/LP variant prevalence, detection patterns under the revised national reimbursement criteria, gene group‐stratified post‐test clinical management, and variant reclassification outcomes. Among 5829 patients (96.6% female; median age, 51 years), 987 (16.9%) carried P/LP variants. Detection rates differed across reimbursement criteria, with the highest rates in patients with ovarian cancer (24.2%) and those meeting multiple criteria (up to 39.3%). Among P/LP carriers, 773 (78.3%) received at least one post‐test clinical action; however, action rates differed substantially across gene groups, ranging from 84.3% among BRCA1/2 carriers to 46.0% among mismatch repair gene carriers. Of 1384 initial variants of uncertain significance, 25 (1.8%) were reclassified as P/LP, identifying 46 additional carriers. Overall variant frequencies were strongly shaped by the breast and ovarian cancer–predominant cohort composition, whereas documented post‐test clinical actions varied across gene groups. Variant reclassification identified additional P/LP carriers, supporting the need for structured recontact and follow‐up pathways.

1 January 2025 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
BPBombi Park
Bombi Park
SCSunHyung Choi
SunHyung Choi
JHJaihong Han
Jaihong Han
SJSo-Youn Jung
So-Youn Jung
SLSeeyoun Lee
Seeyoun Lee
ELEun-Gyeong Lee
Eun-Gyeong Lee
Park B, et al. J Breast Cancer. 2025 Dec;28:e46. https://doi.org/10.4048/jbc.2025.0019